ABEONA THERAPEUTICS INC. 8-K

What Happened
Abeona Therapeutics, Inc. (ABEO) filed a Form 8‑K on June 4, 2026 reporting that it participated in a pre‑Investigational New Drug (Pre‑IND) meeting with the U.S. Food and Drug Administration concerning ABO‑701. ABO‑701 is a recently licensed, radically novel engineered T‑cell therapy targeting Prostate‑Specific Membrane Antigen (PSMA) for prostate cancer. The company described the meeting as constructive and said it continues to target submission of an IND application for ABO‑701 in 2027; official FDA meeting minutes have not yet been received.

Key Details

• Filing date: June 4, 2026 (Form 8‑K).
• Program: ABO‑701 — a PSMA‑targeting engineered T‑cell therapy, recently licensed by the company.
• Timeline: Company continues to target an IND submission for ABO‑701 in 2027.
• Risks/Status: Official FDA minutes are pending; Abeona cautioned the FDA may require additional studies, data, or information and that IND acceptance and authorization to start clinical trials are not guaranteed.

Why It Matters
This update signals progress in Abeona’s oncology pipeline and preserves the company’s stated 2027 IND timeline for ABO‑701, which could be a material value driver if the program advances. However, the notice also highlights regulatory uncertainty—pending FDA minutes and the potential need for more preclinical work mean timelines, costs, and outcomes could change. Investors should weigh this as a development‑stage update and consider the company’s broader risk disclosures and funding needs when assessing impact.